biotech / news / / The Guardian
Mocertatug Rezetecan, known as Mo-Rez, shrank or eliminated tumours in 62% of patients with ovarian cancer where chemotherapy.
GSK's Mo-Rez shrank or eliminated tumors in 62% of ovarian and 67% of endometrial cancer patients.
KEY POINTS
- GSK acquired Mo-Rez from China's Hansoh Pharma in late 2023 and trialed it in 224 patients globally.
- Positive early and intermediate trial data allow GSK to proceed directly to late-stage global trials for Mo-Rez.
- Mo-Rez is projected to be a blockbuster drug, expected to exceed £2bn in annual peak sales.
- GSK's oncology sales rose 43% last year, with four approved cancer drugs and 13 in clinical development.
COMPANIES
Summarized by Newsio from The Guardian. How we summarize →